Abstract:Jiancao Ding, 1 Ying Sun, 2 Kan Zhang, 2 Wei Huang, 2 Mei Tang, 2 Dai Zhang, 2 Yunli Xing 2 1 Department of Geriatrics, First People's Hospital of Zigong, Sichuan, People's Republic of China; 2 Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Yunli Xing, Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yongan Road, Xicheng District, Beijing, 100050, People's Republic of China, Tel +86 13121181469, Fax +86 10 6313 8040, Email Objective: This study explored whether anticoagulation is safe for frail and non-frail elderly patients who have nonvalvular atrial fibrillation (NVAF). Methods: At hospital discharge, the anticoagulant regimen and frailty status were recorded for 361 elderly patients (aged ≥ 75 y) with NVAF. The patients were followed for 12 months. The endpoints included occurrence of thrombosis; bleeding; all-cause death; and cardiovascular events. Results: At hospital discharge, frailty affected 50.42% of the population and the anticoagulation rate was 44.04%. At discharge, age (OR 0.948, P = 0.006), paroxysmal NVAF (OR 0.384, P < 0.001), and bleeding history (OR 0.396, P = 0.001) were associated with a decrease in rate of receiving anticoagulation, while thrombotic events during hospitalization (OR 2.281, P = 0.021) were associated with an increase. Relative to non-frail patients, those with frailty showed a higher rate of ischemic stroke (5.33% cf. 3.01%), bleeding ( P = 0.006) events, and all-cause mortality ( P = 0.001). Relative to the group without anticoagulation, in those with anticoagulation the rate of thrombotic events was lower (6.99 cf. 10.98%) and bleeding events were higher (20.98 cf. 12.72%), but the risk of major bleeding was comparable. Conclusion: In the elderly patients with NVAF, the decision toward anticoagulation therapy at hospital discharge was influenced by age, bleeding history, paroxysmal atrial fibrillation diagnosis, and absence of thrombosis. Frail patients were at greater risk of bleeding and all-cause mortality. Anticoagulation tended to reduce the risk of thrombotic events. Keywords: elderly, non-valvular atrial fibrillation, frailty, anticoagulation Atrial fibrillation (AF) is a common arrhythmia in the elderly population, affecting up to 12% of people aged 80 years and older 1 and can raise the risk of stroke by five-fold. 2 AF and related stroke in the elderly seriously affect their quality of life and greatly increase the burden on the healthcare industry. Frailty is also a common geriatric syndrome that has been associated with adverse events such as disability, hospital-acquired infection, and mortality. 3 Frail elderly patients with AF especially may have a higher risk of stroke and bleeding, and are often complicated with sarcopenia, malnutrition, and multiple comorbidities. Additionally, they are more susceptible to drug side effects. However, the presence of frailty is rarely included as a factor in clinical studies of anticoagulation therapy, and this lack of data confounds management decisions. Although anticoagulation is cost-effective in reducing stroke risk in AF, 4 it is sometimes not applied to the elderly, despite indications, especially in those with frailty. 5 Relevant studies have shown that elderly patients with AF may need timely anticoagulation, yet there is no unified opinion about whether this therapy will improve prognosis. 4,6 More research evidence is needed. This study explored whether anticoagulation is safe for elderly patients with AF, and the influence of frailty on medical decisions. We conducted an overall evaluation of elderly patients with nonvalvular atrial fibrillation (NVAF), aged 75 years and older, aided by a comprehensive geriatric assessment. This study was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University (Research Ethics number 2018-P2-037-02). This study was in compliance with the Declaration of Helsinki. The study enrollment comprised elderly patients with NVAF who were hospitalized in the geriatric and cardiovascular departments of Beijing Friendship Hospital from May 2017 to March 2022. All the subjects were aged 75 years or older, and with AF as verified by ECG (electrocardiogram) or 24-hour ECG with onset ≥30 s. AF types included both paroxysmal (terminating within 7 days, with or without intervention) and persistent (lasting more than 7 days). Patients with any of the following were excluded: AF due to hyperthyroidism; AF combined with mechanical valve or mod -Abstract Truncated-

Clinical outcomes and anticoagulation therapy in elderly non‐valvular atrial fibrillation and heart failure patients

Coagulation Biomarkers and Clinical Outcomes in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Subcohort Study

Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry

Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction

Clinical characteristics and prognostic impact of atrial fibrillation among older patients with heart failure with preserved ejection fraction hospitalized for acute heart failure

Coronary events in elderly patients with non-valvular atrial fibrillation: a prespecified sub-analysis of the ANAFIE registry

Atrial fibrillation type and long-term clinical outcomes in hospitalized patients with heart failure: insight from JROADHF

Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation

Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience

Gastrointestinal bleeding in elderly patients with atrial fibrillation: prespecified All Nippon Atrial Fibrillation in the Elderly (ANAFIE) Registry subgroup analysis

Clinical Profile and Outcomes of Atrial Fibrillation in Elderly Patients with Acute Myocardial Infarction.

Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study

Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis

Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis

Observational study of frailty in older Japanese patients with non-valvular atrial fibrillation receiving anticoagulation therapy

Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation

Temporal trends in initiation of oral anticoagulants and stroke-free survival among elderly and very elderly patients with new onset atrial fibrillation - a 20-year perspective.

The efficacy and safety of NOAC in very elderly atrial fibrillation patients; data from the Korean national health insurance cohort registry

Trajectories of Frailty and Clinical Outcomes in Older Adults With Atrial Fibrillation: Insights From the Shizuoka Kokuho Database

Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study

Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study